Automated quantification of amyloid positron emission tomography: a comparison of PMOD and MIMneuro

ObjectiveThe aim of this study was to examine and compare two automated quantitative software tools (PMOD and MIMneuro) for the quantification of amyloid positron emission tomography (PET).MethodsA total of 30 subjects—15 Alzheimer’s disease (AD) patients and 15 cognitively normal age- and sex-matched controls—were enrolled. All subjects underwent structural volumetric magnetic resonance imaging (MRI) and amyloid PET scans with F-18 florbetaben. Regional standardized uptake value ratios (SUVRs) using the cerebellar cortex as a reference region were obtained using PMOD and MIMneuro.ResultsThe SUVRs using both PMOD and MIMneuro showed high discriminatory power between the AD patients and cognitively normal controls. While PMOD and MIMneuro yielded significantly different SUVRs in some brain regions, the two methods had good overall agreement.ConclusionMIMneuro provides comparable performance to PMOD without the need to acquire brain MRI. Therefore, MIMneuro might be suitable for clinical use to determine amyloid positivity.

[1]  Masanori Ichise,et al.  PET Quantification of 18F-Florbetaben Binding to β-Amyloid Deposits in Human Brains , 2013, The Journal of Nuclear Medicine.

[2]  J. Morris.  The Clinical Dementia Rating (CDR) , 1993, Neurology.

[3]  Duk L. Na,et al.  A validity study on the Korean Mini-Mental State Examination (K-MMSE) in dementia patients , 1997 .

[4]  Andrei G. Vlassenko,et al.  Quantitative Analysis of PiB-PET with FreeSurfer ROIs , 2013, PloS one.

[5]  J. Hardy,et al.  Amyloid deposition as the central event in the aetiology of Alzheimer's disease. , 1991, Trends in pharmacological sciences.

[6]  W. Klunk,et al.  Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B , 2004, Annals of neurology.

[7]  N. Tzourio-Mazoyer,et al.  Automated Anatomical Labeling of Activations in SPM Using a Macroscopic Anatomical Parcellation of the MNI MRI Single-Subject Brain , 2002, NeuroImage.

[8]  E. DeLong,et al.  Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. , 1988, Biometrics.

[9]  John Seibyl,et al.  Partial-Volume Effect Correction Improves Quantitative Analysis of 18F-Florbetaben β-Amyloid PET Scans , 2016, The Journal of Nuclear Medicine.

[10]  H. Gertz,et al.  Individualized quantification of brain β-amyloid burden: results of a proof of mechanism phase 0 florbetaben PET trial in patients with Alzheimer’s disease and healthy controls , 2011, European Journal of Nuclear Medicine and Molecular Imaging.

[11]  Anders M. Dale,et al.  Automatic parcellation of human cortical gyri and sulci using standard anatomical nomenclature , 2010, NeuroImage.

[12]  H. Hall,et al.  [(11)C]PIB-amyloid binding and levels of Abeta40 and Abeta42 in postmortem brain tissue from Alzheimer patients , 2010, Alzheimer's & Dementia.

[13]  S. DeKosky,et al.  Simplified quantification of Pittsburgh Compound B amyloid imaging PET studies: a comparative analysis. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[14]  James Robert Brašić,et al.  In Vivo Imaging of Amyloid Deposition in Alzheimer Disease Using the Radioligand 18F-AV-45 (Flobetapir F 18) , 2010, Journal of Nuclear Medicine.

[15]  Lisa A. Weissfeld,et al.  Inter-rater reliability of manual and automated region-of-interest delineation for PiB PET , 2010, NeuroImage.

[16]  Paul Edison,et al.  Comparison of MRI based and PET template based approaches in the quantitative analysis of amyloid imaging with PIB-PET , 2013, NeuroImage.

[17]  Christer Halldin,et al.  Evaluation of Two Automated Methods for PET Region of Interest Analysis , 2014, Neuroinformatics.

[18]  Osama Sabri,et al.  Evaluation of software tools for automated identification of neuroanatomical structures in quantitative β-amyloid PET imaging to diagnose Alzheimer’s disease , 2016, European Journal of Nuclear Medicine and Molecular Imaging.

[19]  John Seibyl,et al.  Cerebral amyloid-β PET with florbetaben (18F) in patients with Alzheimer's disease and healthy controls: a multicentre phase 2 diagnostic study , 2011, The Lancet Neurology.

[20]  E. Salmon,et al.  18F‐flutemetamol amyloid imaging in Alzheimer disease and mild cognitive impairment: A phase 2 trial , 2010, Annals of neurology.

[21]  M. Mintun,et al.  Amyloid-β Imaging with Pittsburgh Compound B and Florbetapir: Comparing Radiotracers and Quantification Methods , 2013, The Journal of Nuclear Medicine.

[22]  C. Rowe,et al.  Amyloid Imaging with 18F-Florbetaben in Alzheimer Disease and Other Dementias , 2011, The Journal of Nuclear Medicine.

[23]  Nick C Fox,et al.  Amyloid-β 11C-PiB-PET imaging results from 2 randomized bapineuzumab phase 3 AD trials , 2015, Neurology.

[24]  Nick C Fox,et al.  11C-PiB PET assessment of change in fibrillar amyloid-β load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study , 2010, The Lancet Neurology.

[25]  M. Mintun,et al.  Amyloid deposition, hypometabolism, and longitudinal cognitive decline , 2012, Annals of neurology.

[26]  Kewei Chen,et al.  Using positron emission tomography and florbetapir F18 to image cortical amyloid in patients with mild cognitive impairment or dementia due to Alzheimer disease. , 2011, Archives of neurology.

[27]  H. Braak,et al.  Neuropathological stageing of Alzheimer-related changes , 2004, Acta Neuropathologica.

[28]  M. Folstein,et al.  Clinical diagnosis of Alzheimer's disease , 1984, Neurology.

[29]  Paul Maruff,et al.  β-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease , 2007 .

[30]  P. Payoux,et al.  Comparison between PET template-based method and MRI-based method for cortical quantification of florbetapir (AV-45) uptake in vivo , 2013, European Journal of Nuclear Medicine and Molecular Imaging.

[31]  H. Braak,et al.  Phases of Aβ-deposition in the human brain and its relevance for the development of AD , 2002, Neurology.

[32]  S. Lehéricy,et al.  Imaging central nervous system myelin by positron emission tomography in multiple sclerosis using [methyl‐11C]‐2‐(4′‐methylaminophenyl)‐ 6‐hydroxybenzothiazole , 2011, Annals of neurology.

[33]  Paul Maruff,et al.  Beta-amyloid imaging and memory in non-demented individuals: evidence for preclinical Alzheimer's disease. , 2007, Brain : a journal of neurology.

[34]  A. Joshi,et al.  Imaging characteristics and safety of florbetapir (18F) in Japanese healthy volunteers, patients with mild cognitive impairment and patients with Alzheimer’s disease , 2015, Annals of Nuclear Medicine.

[35]  M. Mintun,et al.  Performance Characteristics of Amyloid PET with Florbetapir F 18 in Patients with Alzheimer's Disease and Cognitively Normal Subjects , 2012, The Journal of Nuclear Medicine.

[36]  John Seibyl,et al.  Improved longitudinal [18F]-AV45 amyloid PET by white matter reference and VOI-based partial volume effect correction , 2015, NeuroImage.

[37]  Bengt Långström,et al.  [11C]PIB-amyloid binding and levels of Aβ40 and Aβ42 in postmortem brain tissue from Alzheimer patients , 2009, Neurochemistry International.

[38]  William J. Jagust,et al.  Measurement of Longitudinal β-Amyloid Change with 18F-Florbetapir PET and Standardized Uptake Value Ratios , 2015, The Journal of Nuclear Medicine.

[39]  G. Linazasoro,et al.  IMAGING β-AMYLOID BURDEN IN AGING AND DEMENTIA , 2008, Neurology.